GeroQubit

GeroQubit specializes in de novo longevity drug design, creating novel small molecules specifically for geroscience applications. Key features include: • Target, tissue, and hallmark-driven design • Synthesizable molecules built reaction-first • Calibrated confidence intervals for every score • GPU-free operation for broad accessibility The platform assembles chemical candidates from real, verified reactions and fragments, ensuring that a synthesizable route exists before the molecule is even finalized. This approach contrasts with traditional methods that often generate structures first and then attempt to deduce a synthesis path, frequently leading to unmakeable compounds. GeroQubit provides candidates with detailed predictions on aging signature effects across multiple tissues and identifies engaged hallmarks of aging. Each candidate includes drug-likeness metrics, ADMET safety profiles, and a validated synthesis route, allowing researchers to move directly to laboratory synthesis. The system is built upon extensive aging data, integrating sources like GenAge, CellAge, Open Targets, and DrugAge. This tool is ideal for pharmaceutical companies, biotechnology firms, and academic research institutions focused on geroscience, drug discovery, and the development of new therapeutics for age-related conditions. It provides a robust and transparent framework for generating novel, makeable drug candidates with quantifiable predictions, speeding up the discovery process.